Your session is about to expire
← Back to Search
Anakinra for Cardiac Sarcoidosis (MAGiC-ART Trial)
MAGiC-ART Trial Summary
This trial is testing whether IL-1 blockade with anakinra is safe and effective in patients with cardiac sarcoidosis.
MAGiC-ART Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMAGiC-ART Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 2 & 3 trial • 104 Patients • NCT01809132MAGiC-ART Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with cardiac sarcoidosis.My heart condition was confirmed by a biopsy showing specific inflammation.I am under 21 years old.I have signs of sarcoidosis in my lungs or eyes and at least 2 lab results confirm it.I have a severe heart rhythm problem.My heart's pumping ability is below normal.I have sarcoidosis only in my heart, with no symptoms in my lungs, eyes, or skin.My heart's inner wall has abnormal thinning or structure.My heart condition was confirmed by a biopsy showing specific non-caseating granulomas.My heart condition was confirmed by a biopsy showing specific inflammation.I do not have any ongoing or recent serious infections.I have been diagnosed with cardiac sarcoidosis following specific guidelines.I likely have cardiac sarcoidosis based on specific heart issues and tests.My heart condition was confirmed by a tissue test showing specific inflammation without infection.I have chronic kidney issues or had a severe reaction to contrast dye before.My heart condition was confirmed by a biopsy showing specific inflammation.I am not allergic to Anakinra, E. coli products, or latex.I have been diagnosed with sarcoidosis based on symptoms and lab results, without needing a heart biopsy.My heart condition was confirmed by a tissue diagnosis showing specific inflammation without infection.I haven't had cancer in the last 5 years, except for specific low-risk types.I show signs of sarcoidosis in my lungs or eyes and have at least 2 lab indicators.My lung test shows a high immune cell ratio.I am not on strong immune system suppressing drugs, except for low-dose oral steroids or methotrexate.I have been diagnosed with cardiac sarcoidosis based on specific heart symptoms and tests.I do not have severe anemia; my hemoglobin is above 8 g/dl.My heart condition meets the major or minor criteria listed.I have been diagnosed with cardiac sarcoidosis based on specific criteria.I have not been in another study or taken experimental drugs recently.I have granulomas in organs other than the heart but show signs of heart involvement.My heart condition was confirmed by a tissue test showing specific inflammation without infection.I have been diagnosed with sarcoidosis.I have been diagnosed with cardiac sarcoidosis following specific guidelines.My kidney function is severely reduced.I have swelling in the lymph nodes on both sides of my chest.I have had COVID-19 or been exposed to it recently.I have not received a live vaccine in the last month.
- Group 1: Anakinra
- Group 2: Standard of Care
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Anakinra received clearance from the Food and Drug Administration?
"To reflect its Phase 2 trial status, Anakinra was assigned a safety score of two due to the limited evidence backing up its efficacy."
Has Anakinra been tested in previous experiments?
"Presently, there are 33 active studies researching the potential of Anakinra with 7 trials in their last phase. Though a majority of these proceedings take place within Ile-de-France's Parisian borders, this drug is being studied by researchers at 440 different sites worldwide."
What is the scope of participation for this research endeavor?
"Affirmative. According to records on clinicaltrials.gov, this trial is now recruiting patients that meet the criteria; it was initially posted on October 23rd 2020 and most recently updated November 2nd 2022. This study needs 28 participants from two different medical centres."
Are enrolment opportunities still available for this experiment?
"Yes, clinicaltrials.gov shows that recruitment for this trial has commenced since its original posting on October 23rd 2020 and is still ongoing as of November 2nd 2022. Enrollment requires 28 participants collected from two distinct sites."
What conditions has Anakinra been known to ameliorate?
"Anakinra is commonly prescribed to treat systemic juvenile idiopathic arthritis (sjia) and neonatal-onset multisystem inflammatory disease (nomid). Additionally, this drug may be used in conjunction with steroids or interleukin-1 receptor antagonists."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger